{
    "clinical_study": {
        "@rank": "97427", 
        "arm_group": [
            {
                "arm_group_label": "Low-dose GC1109", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Low-dose Placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "High-dose GC1109", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "High-dose Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "1. BACKGROUND The newly developed anthrax vaccine GC1109 has been proven safe and\n           effective in preclinical studies.\n\n        2. OBJECTIVE\n\n           - To evaluate the immunogenicity and safety of the anthrax vaccine GC1109 in healthy\n           male volunteers.\n\n        3. STUDY DESIGN\n\n             -  single-blinded\n\n             -  randomized\n\n             -  placebo controlled\n\n             -  phase 1 study"
        }, 
        "brief_title": "Efficacy and Safety of Anthrax Vaccine, GC1109", 
        "completion_date": {
            "#text": "December 2009", 
            "@type": "Actual"
        }, 
        "condition": "Anthrax", 
        "condition_browse": {
            "mesh_term": "Anthrax"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Healthy male subjects between 18 and 45 years of age at the time of screening visit\n\n          2. 18.5kg/m2 \u2264BMI < 30kg/m2 at the time of screening visit\n\n          3. Subjects without congenital or chronic disorder\n\n        Exclusion Criteria:\n\n        -"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01867957", 
            "org_study_id": "GC1109_P1_v1.2"
        }, 
        "intervention": [
            {
                "arm_group_label": "Low-dose GC1109", 
                "description": "50ug/dose", 
                "intervention_name": "Low-dose GC1109", 
                "intervention_type": "Biological", 
                "other_name": "GC1109 50ug/dose (0.5 ml) vaccination"
            }, 
            {
                "arm_group_label": "High-dose GC1109", 
                "description": "100ug/dose", 
                "intervention_name": "High-dose GC1109", 
                "intervention_type": "Biological", 
                "other_name": "GC1109 100ug/dose (1.0 ml) vaccination"
            }, 
            {
                "arm_group_label": "Low-dose Placebo", 
                "description": "0.9% Saline 0.5 mL", 
                "intervention_name": "Low-dose Placebo", 
                "intervention_type": "Biological", 
                "other_name": "0.9% Saline 0.5 mL vaccination"
            }, 
            {
                "arm_group_label": "High-dose Placebo", 
                "description": "0.9% Saline 1.0 mL", 
                "intervention_name": "High-dose Placebo", 
                "intervention_type": "Biological", 
                "other_name": "0.9% Saline 1.0 mL vaccination"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "anthrax", 
            "vaccine", 
            "bioterrorism", 
            "efficacy", 
            "safety"
        ], 
        "lastchanged_date": "June 3, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Seoul National University Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Single Blind, Randomized, Placebo Control, Phase I Study to Evaluate the Safety and Immunogenicity of the GC1109 Administered by the Intramuscular Route in Healthy Men", 
        "overall_official": {
            "affiliation": "Seoul National University Hospital", 
            "last_name": "Myoung-don Oh, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Adverse Event", 
            "safety_issue": "Yes", 
            "time_frame": "0 - 28 Days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01867957"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Seoul National University Hospital", 
            "investigator_full_name": "Myoung-don Oh", 
            "investigator_title": "Professor, Division of Infectious Diseases, Department of Internal Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Anti-protective antigen(PA) antibody level (by TNA)", 
                "safety_issue": "No", 
                "time_frame": "Day 14, Day 28"
            }, 
            {
                "measure": "Anti-PA Immunoglobulin G (IgG) (by ELISA)", 
                "safety_issue": "No", 
                "time_frame": "Day 14, Day 28"
            }
        ], 
        "source": "Seoul National University Hospital", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Green Cross Corporation", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "LSK Global Pharma Services Co. Ltd.", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Seoul National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2009", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}